Sep 28, 2017
“I already started getting numerous enquirers regarding your research and practical application of SCP using bone marrow material. People are asking how can they learn more, maybe pay a visit and observe the procedure with their own eyes. Quick and massive feedback, unprecedented.” This from the sponsor of the meeting of the Russian Orthopedic Society meeting in St Petersburg, September 21 to 23 where I had been an invited speaker to introduce Regenerative Orthopedics and Orthobiologics to an audience previously unaware of developments evolving in the United States wherein a patient symptomatic or otherwise affected by osteoarthritis might postpone or avoid a joint replacement with a needle rather than a knife.
What first struck me on our return from the airport on Monday afternoon while driving down the Kennedy was the unending display of outdoor advertising that really obstructs the view of the beautiful skyline of downtown Chicago. My wife and I had just enjoyed unobstructed beauty for five days in St Petersburg. While a case can be made for freedom of speech, I could rapidly adjust to less visual pollution in our City. Next came the pollution of Regenerative Medicine ads appearing in the newspaper when we arrived home and started catching up on the news. I had devoted four weeks developing my evidence based and outcomes supported, scientific presentations prior to departing on September 19 for the St Petersburg meeting, only to return to claims by local health care professionals without scientific authenticity and without evidence based support. While I was speaking at an international clinical conference to orthopedic surgeons; and the media hype appearing in Chicago and suburban newspapers was direct to the public marketing be it in an ad format or Health and Fitness section of a suburban newspaper, professionals have a moral, ethical and professional obligation to present materials based on evidence and science.
Perhaps my criticism is the result of a view of health care from the unique perspective of an Orthopedic Surgeon integrating science and outcomes surveillance with clinical care in his practice. These are the reasons why I was invited to introduce evidence based cellular orthopedics to the international orthopedic community. If you want to take advantage of that knowledge and experience for the care and treatment of your arthritic joint, watch my webinar and visit the website www.ilcellulartherapy.com or call for a consultation 312 475 1893.
Tags: Bone Marrow Concentrate, Clinical Trial. Mitchell B. Sheinkop, Interventional Orthopedics, Orthopedic Surgeon, Pain Management, regenerative medicine, stem cell treatment
Aug 18, 2017
On August 3rd, I wrote a Blog titled” Advancing the Discipline of Cellular Orthopedics”. As readers of my weekly Blog as swell as present and former patients are aware, I have long focused my clinical practice first in joint replacement and now in Cellular Orthopedics, on the integration of patient care and research. When I traded the scalpel for a needle five years ago, I introduced that data collection and research methodology developed during my joint replacement career into the emerging discipline of Regenerative Medicine. Several months ago, I made a major decision to place increasing emphasis on that integration of patient care with research rather than continue to pursue the business model methodology. First the bad news, the diminution of marketing exposure inherent in my decision has temporarily resulted in a drop off in the number of procedures being performed. On the other hand, the international recognition of my efforts has culminated in an invitation to introduce the subspecialty of Cellular Orthopedics at the annual meeting of the Russian/ Ukrainian Orthopedic Association being held in St Petersburg, Russia, September 21st to 23rd. This meeting will be attended by over 1200 orthopedic surgeons from the region and it will be the first-time participants will have been introduced to non-operative alternatives for assisting a patient limited by arthritis of a major joint.
Sponsored by Zimmer-Biomet, Corporation, the largest prosthetic reconstructive company in the world, politics are set aside and the well-being of the human being becomes the only consideration. I am organizing my several presentations following the same educational principles I adhered to when I lectured in St Petersburg, Moscow and Vladivostok in 2004, 2005, and 2006. Then I shared my knowledge of joint replacement surgery and taught how I did things at Rush. Now I will share what I have learned in helping patients postpone, perhaps even avoid a joint replacement presenting at a workshop and then sharing my scientific outcomes data.
It is a personally rewarding opportunity for me as it is an international recognition of my initiatives and lends credence to my decision to have separated myself from the business model pursuit. Imagine my personal satisfaction to be returning by invitation to the birthplaces of my mother and father 85 years after they had been forced to leave? I am experiencing the ultimate reward from my profession.
If you want to personally gain from my Cellular Orthopedic experiences and knowledge, schedule an appointment buy calling 312-475-1893 or view my website and webinars www.ilcellulartherapy.com.
Tags: Bone Marrow Concentrate, cellular orthopedics, Clinical Trial. Mitchell B. Sheinkop, Interventional Orthopedics, Mesenchymal Stem Cell, Orthopedic Care, regenerative medicine, Russian/ Ukrainian Orthopedic Association, stem cell treatment, Zimmer-Biomet
Jul 20, 2017
We now are approaching five-year outcomes regarding the use of Bone Marrow Concentrate for Osteoarthritis of the hip, knee, shoulder and ankle. Bone Marrow contains Adult Mesenchymal Stem (MSC) cells and Growth Factors. In the beginning, the entire informed consent process focused on the MSC in bone marrow as the agent responsible for diminishing pain, improving motion, stopping, at times reversing the progression of osteoarthritis, and potentially regenerating the joint itself. Now we know that equally important to the MSC are the growth factors produced and stored in the bone marrow. Some of the key proteins (Growth factors) include Interleukin-1 Receptor Antagonist Protein (IRAP), Alpha-2-Macroglobulin (A2M), fibrinogen, PDGF, VEGF, and TGF-B to name a few.
The reason we directed our clinical initiatives to Bone Marrow Concentrate is that while Amniotic Fluid contains Hyaluronic Acid, once harvested, sterilized and fast thawed for clinical application, there are no living stem cells left, so Amniotic Fluid Concentrate has no regenerative potential. When it comes to Adipose Derived Stem Cells, in order to liberate the stem cell from the adipocyte, an enzyme, collagenase must be employed. The latter is not approved by the FDA. Additionally, there is no evidence of Growth Factor content in adipose derived tissue.
While I have blogged about the superiority of Bone Marrow Concentrate over all other non-surgical approaches for arthritis, the introduction of the intraosseous adjunct, subchondroplasty, is resulting in even superior outcomes when compared to those who were treated prior to this contemporary version of Cellular Orthopedics. It has been nine months basically since I started injecting Bone Marrow Concentrate into the marrow adjacent to the joint in addition to the intraarticular approach. We already are seeing a better outcome in those who availed themselves of the Intraosseous adjunct. Up until eight weeks ago, my ability to offer contemporary and improved treatment options was limited by preexisting contractual obligations; but now unrestricted, I have expanded my scope of offerings including elevation of subchondroplasty from a clinical trial status to usual and customary adjunct standard of practice option. As well, I now offer an increased opportunity for participation in other clinical trials for the arthritic joint when a patient meets obligatory inclusion criteria determined by the trial sponsor.
If you want to postpone, perhaps avoid a major surgical replacement for an arthritic joint, call for a consultation 847 390 7666
You may visit my web site at IlCellulartherapy.com where you may watch my webinar.
Tags: arthritis, Benefits and Risk, bone marrow, Bone Marrow Concentrate, Clinical Studies, Clinical Trial. Mitchell B. Sheinkop, Interventional Orthopedics, Microfracture surgery, Orthopedics, Osteoarthritis, Pain Management, stem cells, treatment
Jul 13, 2017
Last week, we traveled to Israel to celebrate the wedding of our youngest son. Israel became the destination for the event as Eric and Judith had met there while his music business was subcontracting to Coke and Judith led the International Marketing initiatives for Coke. The event took place on July 5th, at an organic farm in the outskirts of Jerusalem. In such a majestic and historical setting prior to and after the ceremony, there took place several organized tours including one of Jerusalem, another at the Dead Sea and for several, a trip to Petra. It was a relatively small group of the attendees; one in particular, a very close and long-time friend has been the subject of my Blog in years past as I described his return to skiing, biking and fly fishing following a Bone Marrow Concentrate/Growth Factor Concentrate/Stem Cell concentrate intervention. Prior to those procedures, he had been forced to give up his athletic passions for several years because of the limitations imposed by arthritis of both knees.
Above is his activity score from Monday, July 3, when Bob and his wife toured Jerusalem’s Old City including a hike on the ramparts of the wall surrounding the Christian Quarter, the stop and prayer at the Temple Mount and a shopping spree at the Arab Suk (bazaar).
What Bob represents is the potential for continued improvement over several years following a regenerative intervention, a process of which I am continually reminded as time passes and I have a longer follow up of my patients. Our mission and ethos is to help patients with arthritic joints enjoy an active life style and postpone, perhaps avoid joint replacements when arthritic impairment ensues. The documentation from the patient above is one of improving outcome as time passes. While his is an anecdote, our data base increasingly reflects similar happenings for the majority of our patients.
There are now many providers for those with arthritic impairment seeking improved function and less symptoms; and who are not candidates for a joint replacement or who do not want to undergo the major surgical undertaking. In your choice of an Interventional Cellular specialist, inquire about her or his long-term outcomes; not just “will I get a free lunch if I attend a seminar?”
To learn more, call for a consultation 847 390 7666
You may watch my webinar and learn more by visiting my website at Ilcellulartherapy.com
Tags: arthritis, Bone Marrow Concentrate, Clinical Trial. Mitchell B. Sheinkop, Interventional Orthopedics, joint replacement, Knee Pain Relief, Orthopedic Surgeon, Regenerative, stem cells
Jun 15, 2017
It was difficult for me to sit and listen to so many “show and tell” presentations not supported by scientifically overseen outcomes data. Too much anecdote about unproven methodologies; many not compliant with FDA guidance. Basically, it was frequently repeated false news. I was taken aback by what so called physicians are injecting into the joints of their patients. Florida seems to lead the way in the cook book approach to arthritis followed closely by California. Illinois is guilty as well but not the medical community. Despite my negativity about the absence of science, this gathering certainly did not begin to approach the science and integrity of presentation found in the discipline of orthopedic surgery; of particular interest to me was the universal agreement that there is no regenerative potential in Amniotic Fluid Concentrate. A matter of fact, there was not one outcomes paper presented concerning amniotic fluid. It becomes ever so important that a patient choose an experienced, scientifically oriented, regenerative medicine specialist when seeking a non-surgical option for an arthritic knee, hip, ankle or shoulder. The patient must bear in mind that the specialist’s goal is to improve function, diminish pain and postpone, possibly avoid a joint replacement for an arthritic joint. When the arthritis has reached end stage, there are those who should have a joint replacement; only a specialist is equipped to properly advise a patient.
In the orthopedic world, scientific papers are not considered to have significance unless the outcome results have been followed for a minimum of two years and more. Furthermore, the articles in order to be considered authoritative must have statistical significance. It seems that the charlatans and camp followers are offering patients an intervention that is neither FDA compliant nor for which there is scientific outcomes data. The one exception to all the fake news was the presentation by Dr. David Karli of Greyledge Orthobiologics who introduced The Method of Ratios for Assessing PRP and BMC Theraeutic Potential. This novel approach to quantitating and qualitating the injectate I am sure will soon become a standard of care for cellular orthopedics so I will quickly introduce into my practice. The Method of Ratios will allow the clinician to better understand what will be injected into a joint.
The appropriate method of advising an arthritic patient as to whether surgery may be postponed or even avoided begins with a specialty consultation including a comprehensive intake, a physical examination including functional testing, and review of images. Only those with specialty training, board certification and experience both in surgery and in regenerative medicine are able to properly advise the patient. I will again underscore the importance of choosing the Cellular Orthopedic expert and not determining what may be best for you by surfing the cloud.
If you want to become better informed, browse my website www.sheinkopmd.com.
You may watch my webinar at www.ilcellulartherapy.com or call to schedule a consultation (312) 475-1893.
Tags: Amniotic, amniotic fluid, arthritis, BMC Theraeutic Potential, bone marrow, cellular orthopedics, Clinical Studies, Clinical Trial. Mitchell B. Sheinkop, Concentrated Stem Cell Plasma, Dr. David Karli, Greyledge, Interventional Orthopedics, Knee Pain Relief, OrthoBiologic Institute, Platelet Rich Plasma, Regenerative, stem cells
